Evidence map›Paper›PMID 42642530›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026

Plasminogen activator inhibitor-1 promotes the proliferation and blocks TGF-β1-dependent growth inhibition of cholesteatoma keratinocytes by ERK signaling.

Linhan Huang, Wei Pan, Nafisa Tursun, Yang Zhang, Liang Xu, Zhangcai Chi

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Linhan Huang *ENT institute and Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Wei Pan *ENT institute and Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Nafisa TursunNHC Key Laboratory of Hearing Medicine, Fudan University, Shanghai, 200031, PR China.
Yang ZhangENT institute and Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Liang XuDepartment of Pathology, Eye & ENT Hospital, Fudan University, 83 Fenyang Road, Shanghai, China.
Zhangcai ChiENT institute and Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China. 10111260012@fudan.edu.cn.

Funding

Shanghai Municipal Health Bureau 20174Y0062
6 · The paper itself

Abstract

objectivesTo examine the role of PAI-1 plays in the pathophysiology of cholesteatoma and to investigate how TGF-β1 and PAI-1 interact to regulate keratinocyte proliferation.

methodsPAI-1 and TGF-β1 expression levels were assessed in pediatric and adult cholesteatoma specimens. Using an in vitro cholesteatoma keratinocyte model, the impacts of PAI-1 and TGF-β1 on cell proliferation were assessed. ERK signaling pathway involvement was examined to determine the underlying mechanisms.

resultsTGF-β1 and PAI-1 were significantly upregulated in all cholesteatoma tissues, with higher levels observed in pediatric cases. PAI-1 promoted the proliferation of cholesteatoma keratinocytes, whereas TGF-β1 exerted an inhibitory effect. Co-treatment with PAI-1 attenuated TGF-β1 induced growth inhibition. Mechanistically, PAI-1 promoted proliferative through activation of the ERK signaling pathway.

conclusionPAI-1 counteracts the anti-proliferative effects of TGF-β1 via activation of ERK pathway, thereby facilitating the proliferation of cholesteatoma keratinocytes. These findings suggest that PAI-1 contributes to the dysregulated growth characteristic of cholesteatoma and may represent a potential thrapeutic target.

Indexed as

Cell proliferationCholesteatomaERK signalingPAI-1TGF-β1

Identifiers

PMID42642530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.